Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma
NCT07875413Phase 2Not yet recruiting
- Sponsor
- AbelZeta
- Start
- May 2027
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prizloncabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by AbelZeta. Primary endpoints: Overall Response Rate at 24 months and Adverse Events at 24 months. Planned start May 2027; status: not yet recruiting.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07875413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875413.